Acquisitions (Tables)

6 Months Ended

Jun. 30, 2013

Melphalan license [Member]

Acquisition-Date Fair Value of Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following items ($ in 000’s):

Cash consideration	$	3,000
Liability assumed—contingent consideration		4,700
Total purchase consideration	$	7,700

Allos Therapeutics, Inc. [Member]

Schedule of Unaudited Pro Forma Results of Operations

The following unaudited pro forma results of operations for the three and six months ended June 30, 2012 assume the Allos acquisition had occurred on January 1, 2012 ($ in 000’s):

	Three Months Ended June 30, 2012 (As Restated)		Six Months Ended June 30, 2012 (As Restated)
Total revenues	$	82,174	$	153,367
Income from operations	$	17,681	$	26,706
Net income	$	11,182	$	43,210
Basic net income per share	$	0.19	$	0.74
Diluted net income per share	$	0.18	$	0.68

Talon Therapeutics, Inc. [Member]

Acquisition-Date Fair Value of Consideration Transferred

The following table summarizes the purchase price ($ in 000’s):

Cash consideration	$	11.3
Contingent value right		6.5
Spectrum shares of common stock		26.3
Total purchase consideration	$	44.1